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 Using artiﬁcial intelligence, followed by in vivo validation, this study identiﬁed the key cardiac mechanism of action of
empagliﬂozin in heart failure in patients with or without diabetes mellitus.
 The most robust mechanism of action involved the NHE-1 co-transporter with 94.7% accuracy.
 NHE-1 blockade by empagliﬂozin administration in rats restored the antiapoptotic activity of XIAP and BIRC5.
 The beneﬁcial reduction in cardiomyocyte cell death after empagliﬂozin treatment is independent of the presence of
diabetes mellitus.
 Empagliﬂozin could emerge as a new treatment for heart failure patients regardless of their glycemic status.https://doi.org/10.1016/j.jacbts.2019.07.010
ABBR EV I A T I ON S
AND ACRONYMS
ANN = artiﬁcial neural network
DM = diabetes mellitus
HF = heart failure
HFrEF = HF with reduced
ejection fraction




RNAseq = RNA sequencing
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t reThe mechanism of action of empagliﬂozin in heart failure with reduced ejection fraction (HFrEF) was deciphered
using deep learning in silico analyses together with in vivo validation. The most robust mechanism of action
involved the sodium-hydrogen exchanger (NHE)-1 co-transporter with 94.7% accuracy, which was similar for
diabetics and nondiabetics. Notably, direct NHE1 blockade by empagliﬂozin ameliorated cardiomyocyte cell
death by restoring expression of X-linked inhibitor of apoptosis (XIAP) and baculoviral IAP repeat-containing
protein 5 (BIRC5). These results were independent of diabetes mellitus comorbidity, suggesting that empa-
gliﬂozin may emerge as a new treatment in HFrEF. (J Am Coll Cardiol Basic Trans Science 2019;4:831–40)
© 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B oth type 1 and 2 diabetes mellitus(DM) are major risk factors for thedevelopment of cardiovascular dis-
SEE PAGE 841eases, increasing morbidity and mortality (1). For de-
cades, long-term clinical studies of DM have shown
value in reducing glycemic levels without a substan-
tial effect on cardiovascular outcomes and certainly
no beneﬁt in heart failure (HF) (2). The advent of a
new class of agents, sodium-glucose co-transporter 2
inhibitors (SGLT2i), heralds a new era and may repre-
sent a turning point. Indeed, in the EMPA-REG
OUTCOME (Empagliﬂozin Cardiovascular Outcome
Event Trial in Type 2 Diabetes Mellitus Patients)
study, patients with type 2 DM who were at high
risk for cardiovascular events and who received
empagliﬂozin in addition to standard care showed
lower rates of the following compared to those
who received placebo: a) primary composite cardio-
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(3). Similar results with other SGLT2is have been re-
ported subsequently by both randomized clinical tri-
als and observational studies (4,5).SGLT2 receptors are located in the proximal renal
tubule and are responsible for 90% of glucose reab-
sorption into the bloodstream. Inhibition of SGLT2
receptors causes glucosuria and reduces glycemic
levels (6). However, control of glycemic levels in
response to SGLTis alone seems insufﬁcient to
explain the reported cardiovascular beneﬁts. In fact,
the EMPA-TROPISM (Are the “Cardiac Beneﬁts” of
Empagliﬂozin Independent of Its Hypoglycemic
Activity? [ATRU-4]) trial (NCT03485222) is an
ongoing trial that aims to elucidate whether the
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FIGURE 1 Flow Chart Depicting the Machine Learning Approach Used in This Study
See Supplemental Video 1. DM ¼ diabetes mellitus; GEO ¼ Gene Expression Omnibus database; HF ¼ heart failure; TPMS ¼ therapeutic
performance mapping system.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 4 , N O . 7 , 2 0 1 9 Iborra-Egea et al.
N O V E M B E R 2 0 1 9 : 8 3 1 – 4 0 Empagliﬂozin in Heart Failure
833independent mechanism (7). A recent viewpoint
postulated the hypothesis that the beneﬁt of SGLTis
in HF may be mediated by the sodium-hydrogen
exchanger (NHE) rather than by the effect on
glucose reabsorption (8); however, a comprehensive
mechanistic explanation of the extra-renal car-
dioprotective SGLTi effects remains elusive.
Machine learning is an interdisciplinary ﬁeld based
on computational and mathematical models that aims
to unravel key interactions within complex biological
networks (9). It is particularly well suited for inves-
tigating the mechanisms underlying the effects of
drugs, including SGLTis. Accordingly, this study used
deep learning analysis to investigate what the key car-
diac mechanisms may be by which empagliﬂozin exerts
its effects in HF and reduced ejection fraction (HFrEF) in
patients with or without DM (Figure 1). Machine
learning-driven pathways were validated in an in vivo
empagliﬂozin-treated post-infarct HF (MI-HF) rat model.
METHODS
MACHINE LEARNING IN SILICO ANALYSES. Molecular
characterization of HF and DM pathology and drug
treatments. First, extensive and careful review offull-length articles in PubMed was conducted to
obtain information about HF and DM. When speciﬁc
molecular information describing the condition was
found, the articles were thoroughly reviewed to
identify protein/gene candidates to feed the mathe-
matical models. When the evidence of the implication
of a candidate in the condition was judged inconsis-
tent enough to be assigned as an effector, an addi-
tional search was performed speciﬁcally for the
candidate, including all the protein names according
to UniProtKB (UniProt Knowledge Base, Geneva,
Switzerland). No text-mining tools were used to avoid
intrinsic technical biases, and only English-language
articles were included, which accounted for more
than 6,509 items reviewed.
Moreover, empagliﬂozin pharmacological data and
molecular relationships described for HF and DM
were extracted by integrating massive, publicly available
databases such as Drugbank, Reactome, MINT, and Bio-
Grid. All this information accounted for more than
350,000 interactions (Figure 1). Brieﬂy, by integrating
published data, a set of molecular proﬁles characterizing
HF and DM were deﬁned, which were used to build the
protein network and the mathematical model.
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RNA sequencing (RNAseq) dataset (public data avail-
able in Gene Expression Omnibus [GEO], accession
GSE57345 and subseries GSE57338 and GSE26887) of
myocardial tissue data derived from HFrEF patients
with (10) or without DM (11) was thoroughly analyzed
to model the molecular effects of empagliﬂozin in
each scenario. Gene information was mapped one-to-
one to proteins for introduction into the protein
network, which included 280 proteins of interest
(Supplemental Table 1). This collection of experi-
mental pathophysiological signals was used as a list of
principles, termed a “truth table,” which apply to a spe-
ciﬁc condition (i.e., some proteins are overexpressed
only in HF patients with DM) (Figure 1) and allow delin-
eation of the molecular behavior of each situation (12).
Generat ion of mathemat ica l models . Finally,
artiﬁcial neural network (ANN)-based analyses were
used to identify the most relevant pathophysiological
processes implicated in HF and DM. To train the
mathematical models, this large collection of well-
established pathophysiological signals and clinical
information relevant to the pathologies under study
was reviewed. The molecular description of these
input-output signals was investigated as follows:
1. Model inputs, for example, information about
drugs, pathologies, and protein/gene relationships
provided by public databases to assess inhibition
or activation of 1 or more nodes of the protein
network (their targets) triggering a perturbation
through the system.
2. Model outputs, for example, experimental RNAseq
data (upregulated or downregulated genes/pro-
teins) and clinical information.
3. Hidden mechanisms of action (MoAs). Using the
model’s input and output data, mathematical al-
gorithms were generated to trace a change or
perturbation from 1 to another, elucidating the
MoAs that would explain this connection.
The models are then able to weight the relative
value of each protein (node) relationship.
Therapeut ic performance mapp ing system
technology . Details about how therapeutic perfor-
mance mapping system (TPMS) (Anaxomics, Barce-
lona, Spain) machine learning analyses work have
been reported previously (13). Brieﬂy, TPMS incor-
porated massive amounts of biological information
relevant to both the disease(s) and the drug under
study, drawn from curated reports and from public
and private databases (Figure 1). Next, TPMS adopted
the gene expression dynamics stored in the truth
table as a reference framework to shape all the bio-
logical information. Finally, TPMS generatedmathematical models to form complex relationships
between datasets or to ﬁnd patterns in the data
(14,15). The system built an ANN, which was trained
with 1,000 iterations. During this process, the models
generated different MoAs, which progressively
increased in accuracy by correcting itself with
already-known clinical and biomedical information,
and cross-validation with independent sets of data
(Figure 1, Supplemental Video 1). Eventually, the al-
gorithms reached a plateau which yielded the ﬁnal
accuracy performance (maximum ¼ 100%) to explain
the MoA of empagliﬂozin in HFrEF (Figure 1).
POST-INFARCT HEART FAILURE IN VIVO RAT
MODEL. A total of 74 rats were used for the experi-
mental validations. The nondiabetic, post-infarct
heart failure (MI-HF) study was performed in male
Sprague Dawley rats weighing 250 to 280 g, obtained
from Envigo (Huntingdon, United Kingdom). The
diabetic MI-HF study (MI-HF-DM) was performed in
male Wistar rats weighing 160 to 200 g obtained from
Envigo (Barcelona, Spain).
Animals were housed in groups under standard
laboratory condition of 12L:12D cycle. All animals
received food and water ad libitum during the study
(n ¼ 7 to 12 per group). All experiments were con-
ducted in accordance with U.S. National Institutes of
Health Guide for the Care and Use of Laboratory An-
imals and were approved by the Committee for Ani-
mal Experiments.
Induct ion of d iabetes mel l i tus in Wistar
rats . DM was induced by a single intraperitoneal in-
jection of streptozotocin (STZ) (50 mg/kg of body
weight) (catalog number S0130, Sigma-Aldrich, St.
Louis, Missouri) dissolved in freshly prepared 0.1 M
citrate buffer (pH 4.5, catalog number 71402, Sigma-
Aldrich). In order to prevent hypoglycemia in the
ﬁrst 24 h after STZ injection, rats were allowed to
have free access to water with 5% glucose. Three days
after STZ injection, rats with blood glucose levels
>300 mg/dl were considered diabetic.
Induct ion of myocard ia l infarct ion . Initially, ani-
mals were anesthetized using intraperitoneal keta-
mine (75 mg/kg) and medetomidine (0.5 mg/kg)
before being intubated and ventilated under 2% iso-
ﬂurane anesthesia. Rats were randomly allocated to
MI or sham surgery, as described elsewhere (16).
Left-sided thoracotomy was performed by a small
incision between the third and fourth intercostal
spaces. The pericardial sac surrounding the heart was
cut open, but the heart was not exteriorized. The
infarction was performed by ligation of the left
anterior descending coronary artery. Visible blanch-
ing and cyanosis of the anterior wall of the left
ventricle and swelling of the left atrium were taken as
TABLE 1 Mechanisms Involved in Heart Failure and Associated Conditions Considered in
the Mechanistic Study
Pathology Pathological Mechanisms Proteins Implicated*
Heart failure 106
Heart hypertrophy 33
Cardiomyocyte cell death 47




Hyperphagia and dysregulated appetite 135
White adipose tissue formation 5
Hypertension 42
Retention of sodium 42
Hyperuricemia 16
Decreased renal excretion of uric acid 16
Values are n. Bold numbers indicate the total number of proteins implicated in the general condition, later
dissected by more speciﬁc motives. *Number of proteins implicated in each mechanism.
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835indicative of successful ligation. Sham surgery was
identical to the MI surgery but without any ligation.
Exper imenta l des ign and study protocol . Two
weeks after surgery, nondiabetic rats (n ¼ 40) were
fed either with standard rat chow (product R/M-H
V1534-70, Ssniff-Spezialdiäten, Soest, Germany) or
chow containing empagliﬂozin (product BI 10773, in
concentration of 200 mg/kg per day to reach a dose of
30 mg/kg per day), and this was continued for a
period of 12 weeks. After 12 weeks, hearts were
rapidly excised, weighed, and processed for further
analysis. Animals were divided into 4 groups: group 1
(n ¼ 7) were sham rats receiving vehicle treatment;
group 2 (n ¼ 10) were sham rats receiving empagli-
ﬂozin; group 3 (n ¼ 12) were infarcted rats receiving
vehicle treatment; group 4 were infarcted rats
receiving empagliﬂozin.
Immediately after diabetes was induced, the Wis-
tar rats were treated with empagliﬂozin (10 mg/kg per
day) (n ¼ 34). This treatment was maintained for
4 weeks before MI was induced and was continued for
a period of 4 weeks after MI. After 4 weeks, hearts
were rapidly excised, weighed, and processed for
further analysis. Animals were divided into 4 groups:
group 1 (n ¼ 8) were diabetic sham rats receiving
phosphate buffered saline (PBS) for 56 days; group 2
(n ¼ 9) were diabetic sham rats receiving empagli-
ﬂozin for 56 days; group 3 (n ¼ 7) were diabetic
infarcted rats receiving PBS for 56 days; group 4
(n ¼ 10) were diabetic infarcted rats receiving empa-
gliﬂozin for 56 days.
Real t ime PCR. Total RNA from tissues were isolated
by the TRIzol RNA isolation protocol. cDNA was
further isolated from RNA by using the QuantiTecht
RT kit (Qiagen, Venlo, the Netherlands), following the
manufacturer’s instructions. Quantitative real-time
polymerase chain reaction (qRT-PCR) was performed
in a model CFX384 real-time system (Bio-Rad, Phila-
delphia, Pennsylvania) using SYBR Green mix
(Thermo Fisher Scientiﬁc, Waltham, Massachusetts)
was used to determine the relative gene expression.
Gene expression was determined by correcting the
reference gene (36B4), and the calculated values are
expressed relative to the control group per experi-
ment. The primers for BIRC5 and XIAP qRT-PCR used
in this study can be found in Supplemental Table 2.
DATA INTEGRATION AND STATISTICAL ANALYSIS.
The RNAseq data were compiled and processed using
the GEO2R tool, using the neqc method for normali-
zation, allowing identiﬁcation of differential expres-
sion levels and calculation of fold changes. The p
values obtained for each RNA probe were adjusted
using the Benjamini-Hochberg false discovery rate at
a signiﬁcance level of 0.01. Only genes with anadjusted p value of <0.01 and log fold changes of
>0.25 were considered. In the in vivo analysis, gene
expression was determined by correcting the refer-
ence gene (36B4), and the calculated values were
expressed relative to the control group per experi-
ment. The 2-DDCT method for comparing relative
expression results between treatments in real-time
PCR was applied. To compare normally distributed
parameters, one-way analysis of variance (ANOVA)
followed by Tukey post hoc test was used. When data
were not normally distributed, a nonparametric
Kruskal-Wallis test followed by a Mann-Whitney
U test with correction for multiple comparisons was
used. To compare empagliﬂozin with vehicle treatment,
an independent t-test or a Mann-Whitney U test was
used where appropriate. Two-sided test results yielding
a p value of <0.05 were considered statistically signiﬁ-
cant. SPSS statistics (version 23.0, IBM, Armonk, New
York) for Windows (Microsoft, Redmond, Washington)
was used to perform all statistical analysis.
RESULTS
EMPAGLIFLOZIN ACTS UPON A SPECIFIC
HF-RELATED PATHOLOGICAL SIGNATURE. First,
the protein signatures of HFrEF and empagliﬂozin
were deﬁned and an ANN analysis identiﬁed the
processes most likely associated with the beneﬁcial
effects of empagliﬂozin observed in HFrEF
(Supplemental Table 1). Obesity, hypertension, and
hyperuricemia contributed the most to the HF path-
ological signature and encompassed the possible ef-
fects of empagliﬂozin, with 140, 42, and 16 proteins of
interest, respectively. For each of these 3 disorders, a
series of mechanisms and the involved proteins were
TABLE 2 Proteins Known to Be Modulated by Empagliﬂozin
Gene Name Protein Name Reference (PMID)
STAT3 Signal transducer and activator of transcription 3 29311992





IFNG Interferon gamma 29311992
ALDH2 Aldehyde dehydrogenase, mitochondrial 29311992
GCG Glucagon 26590679
INS Insulin 27289126
ACE2 Angiotensin-converting enzyme 2 26880444
BDNF Brain-derived neurotrophic factor 25344694
HDAC1 Histone deacetylase 1 27829948
HDAC2 Histone deacetylase 2 27829948
HDAC3 Histone deacetylase 3 27829948
HDAC8 Histone deacetylase 8 27829948
PMID ¼ unique identiﬁer number used in PubMed for each article.
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the 3 following complementary strategies: 1) Consider
sodium/glucose cotransporter 2, Na(þ)/glucose
cotransporter 2 (SGLT2); 2) consider sodium/
hydrogen exchangers 1 and 3 (NHE1 and NHE3); and 3)
considering empagliﬂozin bioﬂags; those proteins
known to be modulated by the drug (Table 2).
ANN EVALUATES THE RELATIONSHIPS AMONG
PROTEIN SETS INSIDE THE NETWORK, PROVIDING A
PREDICTIVE SCORE. Once the pathological signa-
tures were identiﬁed, the possible relationships be-
tween empagliﬂozin and heart failure, including
associated processes, were evaluated by ANN ana-
lyses. Thus, the study of the MoA of empagliﬂozin
was focused on the following speciﬁc pathways
(motives) of the diseases affected by the treatment:
1) None of the evaluated diseases and motives are
strongly related to SGLT2 according to the estab-
lished criterion (p > 0.3).
2) Considering NHE1 and NHE3 as effectors, 2 condi-
tions appear to be highly related (>75%) to empa-
gliﬂozin’s complete target proﬁle:
Hypertension: retention of sodium is the main
motive identiﬁed, with a predictive score of 80%.
HF: heart hypertrophy and cardiomyocyte cell
death are the main motives identiﬁed, with a
predictive score of 75.6%.
3) Three conditions appear to be highly related
(>75%) to empagliﬂozin’s bioﬂags:
Hyperuricemia: decreased renal excretion of uric
acid is the motive most related to empagliﬂozin,
with 77% of predictive score.
Obesity: the most related motives are hyperphagia
and dysregulated appetite and white adipose
tissue formation.HF: the most related motives are energy-
inefﬁcient myocardial fuel metabolism, oxidative
stress, and inﬂammation.
NHE1 IS RESPONSIBLE FOR THE CARDIAC EFFECTS
OF EMPAGLIFLOZIN IN HFrEF WITH OR WITHOUT
DM. By using the differentially expressed proteins
found to be related to HF and the speciﬁc motives
affected during the pharmacological treatment, the
mathematical models determined the molecular
mechanisms involved in the heart-focused beneﬁcial
effects of empagliﬂozin relative to heart failure in DM
and non-DM patients.
The most robust MoA identiﬁed in this study
involved the cardiac sodium/hydrogen exchanger 1
(NHE1) with 94.7% accuracy (Figure 2, Supplemental
Table 3), which was similar for DM and non-DM pa-
tients, indicating a DM-independent mechanism
(Table 3). This approach describes mainly the miti-
gation of cell death but also the prevention of heart
hypertrophy and the improvement upon an inefﬁ-
cient myocardial fuel metabolism as the potential
heart-mediated mechanisms by which empagliﬂozin
may counteract heart failure.
Direct empagl iﬂoz in-dr iven NHE1 blockade
amel iorates card iomyocyte ce l l death . In this
scenario, the amelioration of cardiomyocyte cell
death was established as the main driver of empa-
gliﬂozin beneﬁcial effects in HFrEF. In the absence of
empagliﬂozin, protein kinases B (AKTs; referred to as
AKT1 to -3 in Figure 2) were identiﬁed as downstream
effectors of NHE1 activation responsible for the in-
duction of baculoviral IAP repeat-containing protein 2
(BIRC2), which in turn induced degradation of
proteasome-mediated X-linked inhibitor of apoptosis
(XIAP) and BIRC5 and prompted the progression of
HFrEF. In empagliﬂozin-enriched models, by inhib-
iting NHE1, repressed AKT1-3 and BIRC2 allowed the
expression of the antiapoptotic mediators XIAP and
BIRC5, ultimately halting HFrEF progression.
To validate these data obtained in silico, mRNA
levels of XIAP and BIRC5, as last effectors of the
pathway, were examined in vivo in an empagliﬂozin-
treated MI-HF rat model. Conﬁrming in silico ﬁnd-
ings, gene expression of XIAP and BIRC5 fell 45% and
36%, respectively, in vehicle-treated MI-HF animals
compared to sham controls (p < 0.01 for both,
respectively). Remarkably, empagliﬂozin-treated MI-
HF animals without diabetes showed upregulation of
XIAP and BIRC5 mRNA expression similar to that in
sham controls and signiﬁcantly higher than vehicle-
treated MI-HF counterparts (p ¼ 0.003 and p ¼ 0.05,
respectively) (Figure 3). More importantly, these
changes in gene expression occurred ubiquitously
regardless of DM presence, further strengthening the
FIGURE 2 NHE1-Identiﬁed Signaling Pathways in Cardiomyocytes in Heart Failure
Each relationship represents a mechanism that may directly or indirectly (via downstream effectors) impact on HF, either through the activation (green arrows) or
inhibition (red arrows) of downstream proteins. AKT1¼ RAC-alpha serine/threonine-protein kinase 1; AKT2¼ RAC-beta serine/threonine-protein kinase 2; AKT3 ¼ RAC-
gamma serine/threonine-protein kinase 3; ATP ¼ adenosine triphosphate; BIRC2 ¼ baculoviral IAP repeat-containing protein 2; BIRC5 ¼ baculoviral IAP repeat-
containing protein 5; LEP ¼ leptin; MAPK1 ¼ mitogen-activated protein kinase 1; MAPK3 ¼ mitogen-activated protein kinase 3; MC ¼ mitochondria.;NHE1 ¼ sodium/
hydrogen exchanger 1; NOS2 ¼ nitric oxide synthase ¼ inducible; PCr ¼ phosphocreatine. ; PDH ¼ pyruvate dehydrogenase; RPTOR ¼ regulatory-associated protein
of mTOR; SR ¼ sarcoplasmic reticulum; TCA ¼ tricarboxylic acid; XIAP ¼ E3 ubiquitin-protein ligase XIAP.
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837in silico predictions. Indeed, empagliﬂozin-treated
MI-HF-DM animals showed upregulation of XIAP
and BIRC5 mRNA expression similar to sham controls
and signiﬁcantly higher than vehicle-treated MI-HF-
DM counterparts (p ¼ 0.01 and p ¼ 0.005, respec-
tively) (Figure 3). Thus, empagliﬂozin-driven NHE1
inhibition ultimately counteracted reduced function
of XIAP and BIRC5.
Additionally, the analyses also suggested that
empagliﬂozin could further ameliorate car-
diomyocyte cell death by inhibiting the AKT-
dependent regulation- associated mTOR protein
(RPTOR) and by down-regulation of nitric oxide syn-
thase (NOS2)-inducible actions (Figure 2).
DISCUSSION
The EMPA-REG OUTCOME trial reported that empa-
gliﬂozin exerted cardiovascular beneﬁts which did
not depend on its effects on blood glucose. This
observation led to the hypothesis that empagliﬂozinexerted an effect on the myocardium independent of
its inhibition of SGLT2 in the kidneys, thereby
beneﬁting HF patients (6). The exact mechanism re-
mains unknown, but it was postulated to have a
direct action on the heart. The present study used
artiﬁcial intelligence and machine learning, further
validated in an in vivo animal model, to investigate
whether empagliﬂozin could exert direct effects on
the heart and whether these effects were the same for
patients with and without DM.
This study has 2 main ﬁndings. First, these results
validate the fact that empagliﬂozin interacts with the
cardiac Naþ/Hþ exchanger NHE1 directly and iden-
tiﬁes a mechanistic pathway acting primarily by
reducing cardiomyocyte cell death, the main effector
of its cardioprotective effects. Indeed, the activity of
cardiac NHE1 seems to be increased in HFrEF pa-
tients, and previous data in experimental models
(17–21) showed that NHE1 inhibition attenuated car-
diomyocyte injury, remodeling, systolic dysfunction,
and ultimately HF. Second, these data suggest that
TABLE 3 Mathematical Models Generated in This Study*
Mathematical Models Stimulus Response Restrictions







GSE57345 subseries GSE57338 dataset








*The stimulus, response, and restrictions included in each model are shown.
DM ¼ diabetes mellitus; GSE designations ¼ Gene Expression Omnibus accession and subseries; HF ¼ heart
failure; NHE1 ¼ sodium-hydrogen exchanger-1.
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838the cardiac effects of empagliﬂozin are independent
of the presence of DM.
Uthman et al. (22) reported that SGLT2i reduced
cardiac cytosolic Naþ and cytosolic Ca2þ concentra-
tions by inhibiting NHE1 in mouse cardiomyocytes.
Cardiac NHE1 activity and cytosolic Naþ were
measured in the presence of clinically relevant con-
centrations of empagliﬂozin (1 mmol/l), dapagliﬂozin
(1 mmol/l), and canagliﬂozin (3 mmol/l). All 3 SGLT2is
bound with high afﬁnity to the extracellular Naþ-
binding site of NHE1 (23). Recently, Baartscheer
et al. (23) proposed a possible relationship between
empagliﬂozin and NHE1 inhibition in rats and rabbits.
In their study, an increase in extracellular glucose
produced an increase in cytosolic levels of Naþ and
Ca2þ, an effect that was inhibited by empagliﬂozin.
The effects of empagliﬂozin were strongly reduced
after cells were pre-treated with the NHE1 inhibitor
cariporide. In addition, empagliﬂozin affected cyto-
solic Naþ and NHE1 ﬂux in the absence of extracel-
lular glucose, which demonstrated its putative effects
in normoglycemic conditions.
These mechanistic studies have the power to
address speciﬁc mechanisms in detail, but the
unravelling of the global molecular effects of empa-
gliﬂozin in HFrEF with or without DM requires the
integration of complex big data, best handled by
artiﬁcial intelligence and deep learning analyses.
Considering all possible empagliﬂozin-derived car-
diac mechanisms, the present analysis pinpointed
NHE1 modulation as the most likely effector of the
beneﬁcial effects. Moreover, amelioration of car-
diomyocyte cell death was found to be the most
important effect of empagliﬂozin in HF.
Most importantly, the algorithm predicted a mod-
ulation of AKTs resulting in an inability of BIRC2 to
degrade the antiapoptotic factors XIAP and BIRC5.
XIAP expression was found to be decreased in failing
human hearts, suggesting that this potent inhibitor of
apoptosis may play a key role in protecting the heart
from cell damage (24,25). Using an adenoviral-
associated vector, Piacentino et al. (24) increasedXIAP expression in neonatal rat cardiomyocytes,
which inhibited caspase-3/7 activity, showing a
reduction of myocardial injury. Relative to BIRC5, Lee
et al. (26) found that overexpression of this pathway
may attenuate the progression of LV systolic
dysfunction in doxorubicin-induced cardiomyopathy.
Furthermore, Levkau et al. (27) showed that cardiac-
speciﬁc deletion of BIRC5 pathway resulted in pre-
mature cardiac death caused by a dramatic reduction
in total cardiomyocyte numbers. Again, using
adenoviral vectors to restore this pathway (through
restoration of survivin) expression in cardiomyocytes
inhibited doxorubicin-induced apoptosis, induced
DNA synthesis, and promoted cell cycle progression
(27). Following this rationale and, to further conﬁrm
the present study’s in silico data, mRNA levels of both
XIAP and BIRC5 were measured in an in vivo MI-HF
rat model. In agreement with existing studies,
both expression levels of XIAP and BIRC5 were
substantially lower in vehicle-treated animals with
dysfunctional myocardium. Remarkably, in the
empagliﬂozin-treated groups, expression levels of
both XIAP and BIRC5 returned to normal, thus they
were able to exert their antiapoptotic effects.
The present study was designed to investigate
whether the MoA of empagliﬂozin in HF in patients
with DM was different from that in patients without
DM. Surprisingly, the most robust MoA identiﬁed
here was identical in both groups, suggesting that
empagliﬂozin may have value in treating HFrEF pa-
tients regardless of their glycemic status, acting to
ameliorate adverse cardiac remodeling. In other
words, empagliﬂozin, currently indicated only for the
treatment of DM, may eventually be repurposed to
treat patients with HFrEF. Several ongoing random-
ized clinical trials are testing the value of SGLTi in HF
patients (both with reduced and preserved ejection
fraction) with and without DM.
The mathematical models reported here were
robust, and each link described is validated in the
existing research publications. However, there is an
ongoing discussion about the mathematical algo-
rithms used in artiﬁcial intelligence, often termed
“black boxes,” because sometimes it may not be easy
to follow the determination of the output, no matter
how good or reliable this may be. This study’s anal-
ysis took a massive amount of collected information
and analyzed it for hidden patterns in the data that
would be otherwise inaccessible to human stand-
alone analysis, to understand how the drug could
lead to a speciﬁc clinical outcome. These algorithms
are widely used in other ﬁelds, and the techniques are
among the best understood and developed, with
time-tested characteristics which ensure an accurate
FIGURE 3 mRNA Levels of Antiapoptotic Proteins XIAP and BIRC5 In Vivo
(A) Upper panels show nondiabetic rats. (B) Lower panels show diabetic rats. Data are mean  SEM. *p < 0.05 vs. empagliﬂozin-MI and Vehicle-Sham. One-way
ANOVA followed by Tukey post hoc test was used for normally distributed data, whereas Kruskal-Wallis followed by Mann-Whitney U test was used for non-normally
distributed data. Abbreviations as in Figure 2.
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839application. A key differentiating feature of deep
learning compared with other subtypes of artiﬁcial
intelligence is the ability to operate without external
guidance to draw conclusions. The neural network is
not designed by humans, rather, the number of layers
is determined by the data itself. Deep ANNs have used
primarily supervised learning, with training from
known patterns and labeled input data (truth table) to
prospect reliable insights in large datasets. At the
same time, all the outputs from the algorithm are
restricted by the current scientiﬁc and medical stan-
dards. Taken together, all this limits human bias, and
the algorithm can act as a hypothesis-free, indepen-
dent data-driven analysis (28).
STUDY LIMITATIONS. However, this study has some
limitations. The same premise that makes the models
robust also serves as a potential downside. Specif-
ically, the information considered here has already
been described or uploaded in public repositories,
which in turn limits the capacity of the analyses to
incorporate data that have not been yet collected. The
data reported here are valid for HFrEF and cannot beextrapolated to HF with preserved ejection fraction
(HFpEF). Further research is required to better un-
derstand the MoA of empagliﬂozin in HFpEF.
CONCLUSIONS
Deep learning in silico analyses, together with in vivo
validation, allowed deciphering the MoA of empagli-
ﬂozin in HFrEF. Our data suggest that empagliﬂozin in-
teracts and blocks the NHE1 co-transporter at the
cardiomyocyte level, triggering a signaling cascade that
halts detrimental cell death. These results were inde-
pendent of DM comorbidity, suggesting that empagli-
ﬂozin may emerge as a new treatment in HFrEF.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The MoA
of empagliﬂozin in HFrEF was deciphered by using deep
learning in silico analyses together with in vivo validation.
The most robust MoA involved the sodium-hydrogen
exchanger-1 (NHE1), which was similar for diabetics and
nondiabetics. Notably, direct NHE1 blockade by
empagliﬂozin ameliorated cardiomyocyte cell death.
TRANSLATIONAL OUTLOOK: Empagliﬂozin, in
addition to its renal effects, has direct cardioprotective
effects at the cardiomyocyte level. These effects were
independent of DM comorbidity, suggesting that
empagliﬂozin may emerge as a new treatment in HFrEF.
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